Cancer History ProjectConversation with The Cancer LetterFree Bill McGivney: How NCCN guidelines came to play a role in payment for cancer therapy March 19, 2021Vol.47 No.11By Paul Goldberg
Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval March 12, 2021Vol.47 No.10By Paul Goldberg
Conversation with The Cancer Letter Working in concert with NCI’s $500M data federation in childhood cancer, St. Jude demonstrates utility of its genomic database March 12, 2021Vol.47 No.10By Matthew Bin Han Ong
Cancer History ProjectConversation with The Cancer LetterFree Bob Young: NCCN is a case study in keeping what works and discarding what doesn’t March 12, 2021Vol.47 No.10By Paul Goldberg
FreeIn the Archives The March, NCI oral history, and the Oncology Nursing Society March 12, 2021Vol.47 No.10
Conversation with The Cancer Letter Not for sale: Fox Chase Cancer Center March 05, 2021Vol.47 No.09By Paul Goldberg
Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation” March 05, 2021Vol.47 No.09By Paul Goldberg
NASEM: Reduce cancer drug waste by reformulating development, payments, dosing March 05, 2021Vol.47 No.09By Alexandria Carolan
Cancer History ProjectFree A 25-year retrospective: How NCCN changed the way cancer medicine is practiced—and paid for March 05, 2021Vol.47 No.09By Paul Goldberg
